stockrow
Friday 6 November 2026
Export MRKR’s income statement to Excel — free account
MARKER THERAPEUTICS, INC.
MRKR Healthcare Biotechnology
MARKER THERAPEUTICS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 46.2% from fiscal 2024.
- Revenue
- −51.0%
- EPS
- +69.0%
- Free cash flow
- −97.8%
Quarter to June 2026, against a year earlier
0.92
0.02
+2.22%
Follow MRKR
Alert me
MARKER THERAPEUTICS, INC. (MRKR) P/E ratio
MARKER THERAPEUTICS, INC. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 28.0× (March 2017) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| 17 more quarters | Free account |
Against its own ten years
Low 0.0×
High 28.0×
Ten-year median
0.0×
Current reading's percentile
94
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NEUP Neuphoria Therapeutics Inc. compare | n/m |
| PLUR Pluri Inc. compare | n/m |
| MRKR MARKER THERAPEUTICS, INC. | n/m |
| ADAPY Adaptimmune Therapeutics PLC compare | n/m |
| ATYR aTyr Pharma, Inc. compare | n/m |
| VAXX Vaxxinity, Inc. compare | n/m |
| CTXR Citius Pharmaceuticals, Inc. compare | n/m |
| ABOS Acumen Pharmaceuticals, Inc. compare | n/m |
| KYNB Kyntra Bio Inc compare | 0.1× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)